





CONTAINS CONFIDENTIAL PATIENT INFORMATION ETEPLIRSEN (EXONDYS 51)

Prior Authorization of Benefits (PAB) Form

Complete form in its entirety and fax to:
Prior Authorization of Benefits Center at 1-844-512-9004
Provider Help Desk 1-800-454-3730

Patient Name: Prescribing Physician: Physician Address: Physician Phone #: Physician Fax #: Physician Specialty:		
Patient DOB: Patient DOB: Physician Phone #: Physician Fax #: Physician Specialty:		
Patient DOB: Physician Phone #: Physician Fax #: Physician Specialty:		
Date of Rx: Physician Fax #: Physician Specialty:		
Physician Specialty:		
Patient Email Address: Physician DEA:		
Physician NPI#:		
Physician Email Address:		
3. MEDICATION 4. STRENGTH 5. DIRECTIONS 6. QUANTITY PER 30 [
Specify:		
8. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request. Prior authorization is required for Exondys 51 (eteplirsen). Payment will be considered for patients when the following criteria are met: Patient has a diagnosis of Duchenne muscular dystrophy (DMD) with mutation amenable to exon 51 skipping confirmed by genetic testing (attach results of genetic testing); and 2) Is prescribed by or in consultation with a physician who specializes in the treatment of Duchenne muscular dystrophy; and 3) Patient is currently ambulatory; and 4) A baseline 6-Minute Walk Distance (6MWD) is provided and patient is able to achieve a distance of at least 180 meters while walking independently; and 5) Patient is currently stable on an oral corticosteroid regimen for at least 6 months; and 6) Is dosed based on FDA approved dosing: 30 mg/kg once weekly; and 7) Medication is to be administered by a healthcare professional in member's home by home health or in a long-term care facility. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. When criteria for coverage are met, an initial authorization will be given for 6 months. Requests for continuation of therapy will be considered at 6 month intervals when the following criteria are met: 1) Patient has demonstrated a response to therapy as evidenced by remaining ambulatory (able to walk with or without assistance, not wheelchair dependent); and 2) An updated 6MWD is provided documenting patient is able to achieve a distance of at least 180 meters. Initial Requests Does Prescriber specialize in treatment of DMD? Pyes No If no, note consultation with Specialist: Consultation date: Physician name & phone:		







CONTAINS CONFIDENTIAL PATIENT INFORMATION ETEPLIRSEN (EXONDYS 51)

Prior Authorization of Benefits (PAB) Form

Complete form in its entirety and fax to:
Prior Authorization of Benefits Center at 1-844-512-9004

PATIENT NAME:	PATIENT ID #:	
Is patient ambulatory (able to walk with or w	vithout assistance, not wheelchair bound)? ☐ Yes ☐ No	
Result of baseline 6MWD (in meters):Date completed: Is patient currently stable on an oral corticosteroid regimen for at least 6 months? No Yes (document below)		
Oral corticosteroid trial: Drug name:	Strength:	
Renewal Requests		
Does patient remain ambulatory (able to walk with or without assistance, not wheelchair bound)? ☐ Yes ☐ No		
Result of subsequent 6MWD (in meters):	Date completed:	
9. PHYSICIAN SIGNATURE		
Proceedings on Authorized Circulary		
Prescriber or Authorized Signature Prior Authorization of Benefits is not the practice of medicine or the sub-	Date Stitute for the independent medical judgment of a treating physician. Only a treating physician can determine what	
medications are appropriate for a patient. Please refer to the applicable provider certifies that the information provided is true, accurate, and con Note: Payment is subj	e plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting applete and the requested services are medically indicated and necessary to the health of the patient. ect to member eligibility. Authorization does not guarantee payment.	
The document(s) accompanying this transmission may co	ontain confidential health information that is legally privileged. This information is intended only authorized recipient of this information is prohibited from disclosing this information to any other	
party unless required to do so by law or regulation.		
	ed that any disclosure, copying, distribution, or action taken in reliance on the contents of d this information in error, please notify the sender immediately and arrange for the return or	